Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis

被引:10
作者
Carrascosa, J. M. [1 ]
Toro Montecinos, M. [1 ]
Ballesca, F. [1 ]
Teniente Serra, A. [2 ,3 ]
Martinez Caceres, E. [2 ,3 ]
Ferrandiz, C. [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Dept Dermatol, Badalona, Spain
[2] Germans Trias & Pujol Univ Hosp & Res Inst, Div Immunol, Barcelona, Spain
[3] Univ Autonoma Barcelona, Dept Cellular Biol Physiol & Immunol, Badalona, Spain
关键词
Psoriasis; biological therapy; adalimumab trough serum levels; TO-SEVERE PSORIASIS; PLAQUE PSORIASIS; CROHNS-DISEASE; INFLIXIMAB; EFFICACY; MODERATE; IMMUNOGENICITY; STRATEGIES; ANTIBODIES; MANAGEMENT;
D O I
10.1080/09546634.2017.1341619
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The possibility of monitoring serum drug levels has opened the door to optimising biologic therapy. To consolidate this advance, it is imperative to demonstrate an adequate correlation between serum drug levels and clinical course.Objectives: To investigate whether a correlation exists between adalimumab levels and clinical response measured as absolute PASI.Methods: In a prospective cohort study, we enrolled 51 patients with psoriasis treated with adalimumab for at least 16s. Patients received approved doses of adalimumab, but after 52 s the dosing interval could be modified according to clinical criteria. Excellent response was defined as PASI 3, appropriate response as PASI >3 and 5 and inappropriate response as PASI>5. Correlations were calculated using Spearman's correlation test.Results: A total of 92 serum samples from 51 patients were analysed. Significant differences were found in serum trough levels between patients achieving an excellent response (6.46g/mL), versus an appropriate (2.5g/mL) and an inappropriate response (2g/mL). The therapeutic range for adalimumab serum levels was from 3.30 to 7.30g/mL.Conclusions: We found an adequate correlation between drug serum levels and PASI scores. Monitoring of absolute PASI and serum levels can provide a personalised and cost-effective evaluation.
引用
收藏
页码:140 / 144
页数:5
相关论文
共 18 条
[1]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[2]   Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis [J].
Bartelds, Geertje M. ;
Wijbrandts, Carla A. ;
Nurmohamed, Michael T. ;
Stapel, Steven ;
Lems, Willem F. ;
Aarden, Lucien ;
Dijkmans, Ben A. C. ;
Tak, Paul Peter ;
Wolbink, Gerrit Jan .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :921-926
[3]   Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies [J].
Carrascosa, J. -M. ;
van Doorn, M. B. A. ;
Lahfa, M. ;
Nestle, F. O. ;
Jullien, D. ;
Prinz, J. C. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (11) :1424-1430
[4]   Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice [J].
Carrascosa, Jose-Manuel ;
Garcia-Doval, Ignacio ;
Perez-Zafrilla, Beatriz ;
Carretero, Gregorio ;
Vanaclocha, Francisco ;
Dauden, Esteban ;
De la Cueva-Dobao, Pablo ;
Belinchon, Isabel ;
Alsina, Merce ;
Lopez-Estebaranz, Jose-Luis ;
Ferran, Marta ;
Torrado, Rosa ;
Rivera, Raquel ;
Carazo, Cristina ;
Barboza, Lorena ;
Ferrandiz, Carlos .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (06) :502-506
[5]   Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment [J].
Casteele, N. Vande ;
Ballet, V. ;
Van Assche, G. ;
Rutgeerts, P. ;
Vermeire, S. ;
Gils, A. .
GUT, 2012, 61 (02) :321-321
[6]   Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects [J].
Krieckaert, C. L. M. ;
Nair, S. C. ;
Nurmohamed, M. T. ;
van Dongen, C. J. J. ;
Lems, W. F. ;
Lafeber, F. P. J. G. ;
Bijlsma, J. W. J. ;
Koffijberg, H. ;
Wolbink, G. ;
Welsing, P. M. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) :361-368
[7]  
Lecluse LLA, 2010, ARCH DERMATOL, V146, P127, DOI 10.1001/archdermatol.2009.347
[8]   Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study [J].
Manriquez, J. ;
Alsina-Gibert, M. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2017, 42 (01) :14-20
[9]   Psoriasis 2 - Current and future management of psoriasis [J].
Menter, Alan ;
Griffiths, Christopher E. M. .
LANCET, 2007, 370 (9583) :272-284
[10]   Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis [J].
Menting, S. P. ;
Sitaram, A. S. ;
Bonnerjee-van der Stok, H. M. ;
de Rie, M. A. ;
Hooft, L. ;
Spuls, Ph I. .
BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (04) :875-883